DE602006018152D1 - Triazolderivate als modulatoren von dopamin-d3-rezeptoren - Google Patents

Triazolderivate als modulatoren von dopamin-d3-rezeptoren

Info

Publication number
DE602006018152D1
DE602006018152D1 DE602006018152T DE602006018152T DE602006018152D1 DE 602006018152 D1 DE602006018152 D1 DE 602006018152D1 DE 602006018152 T DE602006018152 T DE 602006018152T DE 602006018152 T DE602006018152 T DE 602006018152T DE 602006018152 D1 DE602006018152 D1 DE 602006018152D1
Authority
DE
Germany
Prior art keywords
4alkyl
group
haloc1
4alkoxy
4alkanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018152T
Other languages
German (de)
English (en)
Inventor
Giorgio Bonanomi
Fabio Romano Di
Elettra Fazzolari
Dieter Hamprecht
Fabrizio Micheli
Luca Tarsi
Silvia Terreni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517202A external-priority patent/GB0517202D0/en
Priority claimed from GB0517181A external-priority patent/GB0517181D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602006018152D1 publication Critical patent/DE602006018152D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602006018152T 2005-08-22 2006-08-18 Triazolderivate als modulatoren von dopamin-d3-rezeptoren Active DE602006018152D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0517202A GB0517202D0 (en) 2005-08-22 2005-08-22 Compounds
GB0517181A GB0517181D0 (en) 2005-08-22 2005-08-22 Compounds
PCT/EP2006/008200 WO2007022933A1 (en) 2005-08-22 2006-08-18 Triazole derivatives as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
DE602006018152D1 true DE602006018152D1 (de) 2010-12-23

Family

ID=37309176

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018152T Active DE602006018152D1 (de) 2005-08-22 2006-08-18 Triazolderivate als modulatoren von dopamin-d3-rezeptoren

Country Status (6)

Country Link
US (1) US7799815B2 (US06653308-20031125-C00015.png)
EP (1) EP1919908B1 (US06653308-20031125-C00015.png)
JP (1) JP5237807B2 (US06653308-20031125-C00015.png)
AT (1) ATE487715T1 (US06653308-20031125-C00015.png)
DE (1) DE602006018152D1 (US06653308-20031125-C00015.png)
WO (1) WO2007022933A1 (US06653308-20031125-C00015.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1745040T1 (sl) * 2004-02-23 2010-04-30 Venue Glaxo Group Ltd Derivati azabiciklo(3.1.0)heksana, uporabni kot modulatorji dopaminskih receptorjev d3
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
EP1891056B1 (en) * 2005-06-14 2010-10-13 Glaxo Group Limited Novel compounds
EP2719384B1 (en) 2005-07-27 2018-08-08 Otsuka America Pharmaceutical, Inc. Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8222266B2 (en) * 2006-04-03 2012-07-17 Glaxo Group Limited Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
WO2010150281A2 (en) 2009-06-26 2010-12-29 Panacea Biotec Ltd. Novel azabicyclohexanes
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN113956157B (zh) * 2021-11-18 2024-05-03 西安都创医药科技有限公司 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
DE60305519T2 (de) * 2002-10-07 2006-11-23 Glaxo Group Ltd., Greenford Sulfonamidderivate als antipsychotische mittel
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
SI1745040T1 (sl) 2004-02-23 2010-04-30 Venue Glaxo Group Ltd Derivati azabiciklo(3.1.0)heksana, uporabni kot modulatorji dopaminskih receptorjev d3
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
EP1891056B1 (en) 2005-06-14 2010-10-13 Glaxo Group Limited Novel compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517187D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071152A1 (es) 2006-04-03 2007-12-16 Glaxo Group Ltd Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
GB0616574D0 (en) 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20090221593A1 (en) 2009-09-03
EP1919908B1 (en) 2010-11-10
JP2009504791A (ja) 2009-02-05
EP1919908A1 (en) 2008-05-14
JP5237807B2 (ja) 2013-07-17
WO2007022933A1 (en) 2007-03-01
ATE487715T1 (de) 2010-11-15
US7799815B2 (en) 2010-09-21

Similar Documents

Publication Publication Date Title
DE602006018152D1 (de) Triazolderivate als modulatoren von dopamin-d3-rezeptoren
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
NO20064309L (no) Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
ATE484502T1 (de) Neue verbindungen
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
GB0507601D0 (en) Compounds
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20090188A1 (es) Compuestos heterociclicos como moduladores de la senda de hedgehog
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
WO2006078621A3 (en) 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
ECSP088253A (es) Derivados de azol y tiazol y sus usos
PE20110995A1 (es) DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
AR050617A1 (es) Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas
PE20091436A1 (es) Derivados de sulfonamidas sustituidas como moduladores b1r
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων